35
Participants
Start Date
October 18, 2010
Primary Completion Date
July 15, 2011
Study Completion Date
July 15, 2011
Inhaled FF 200mcg/GW642444M 25mcg
All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
GSK Investigational Site, Hradec Králové
GSK Investigational Site, Prague
GSK Investigational Site, Bratislava
Lead Sponsor
GlaxoSmithKline
INDUSTRY